Wegovy delivered substantial weight loss in women across all menopause stages, plus heart and migraine protection, shown in new data at the European Congress on Obesity Novo Nordisk Novo Nordisk announced data demonstrating that Wegovy (semaglutide 2.4 mg and 7.2 mg) delivers substantial and consistent weight-loss results for women with obesity across reproductive life stages, from premenopausal years through the menopause transition and beyond
Anti-Doping Agency for participant registration records
Eating smaller, protein-rich meals every 2-3 hours keeps your stomach partially full without overwhelming your slowed digestion, while sugary or high-fat foods trigger more intense nausea in most patients
Further research should assess the balance between its potential benefits and risks, particularly in patients with concurrent infections or immunocompromised states
They truly care about their patients by offering first-class services
The muscle growth guide and safe muscle preservation strategies cover resistance training principles that apply directly to people on GLP-1 medications